2012
MDV3100-08: A phase I open-label, dose-escalation study evaluating the safety, tolerability, and pharmacokinetics of MDV3100 in women with incurable breast cancer.
Elias A, Richer J, LoRusso P, Peterson A, Steinberg J, Mordenti J, Lopez C, Hudis C, Traina T. MDV3100-08: A phase I open-label, dose-escalation study evaluating the safety, tolerability, and pharmacokinetics of MDV3100 in women with incurable breast cancer. Journal Of Clinical Oncology 2012, 30: tps668-tps668. DOI: 10.1200/jco.2012.30.15_suppl.tps668.Peer-Reviewed Original ResearchPhase 2 doseIncurable breast cancerBreast cancerAndrogen receptorDay 1PK samplesDay 8Dose-escalation stageOverall survival benefitDose-escalation studyPhase 1 studyAR nuclear translocationInhibition of androgenPotential therapeutic strategyPK samplingAdverse eventsDaily dosingSurvival benefitAR expressionHistologic subtypeDiscontinuation criteriaPreclinical activityProstate cancerTumor assessmentMDV3100
2010
189 Preclinical activity of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in combination with irinotecan in ovarian and triple negative breast cancers
Nechiporchik N, Lieb K, Marquette L, Polin L, Peters G, Chen A, Ethier S, LoRusso P, Burger A. 189 Preclinical activity of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in combination with irinotecan in ovarian and triple negative breast cancers. European Journal Of Cancer Supplements 2010, 8: 64. DOI: 10.1016/s1359-6349(10)71894-2.Peer-Reviewed Original Research
1996
Preclinical anticancer activity of cryptophycin-8.
Corbett T, Valeriote F, Demchik L, Polin L, Panchapor C, Pugh S, White K, Knight J, Jones J, Jones L, LoRusso P, Foster B, Wiegand R, Lisow L, Golakoti T, Heltzel C, Ogino J, Patterson G, Moore R. Preclinical anticancer activity of cryptophycin-8. Journal Of Experimental Therapeutics And Oncology 1996, 1: 95-108. PMID: 9414393.Peer-Reviewed Original Research